Galina Grebennikova
Research Subjects
Galina Grebennikova has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
A.P. Dzhaimbetova
Kazakhstan Association of Sexual and Reproductive Health; UNFPA, Almaty
2 shared publications- Dilrabo Kayumova
Department of Obstetrics and Gynecology, Tashkent State Medical University, Tashkent 100109, Uzbekistan
2 shared publications - F.A. Gafurova
Center for the Development of Professional Qualifications of Medical Workers, Tashkent
2 shared publications G.T. Myrzabekova
Center for Molecular Medicine, Almaty
2 shared publications- Irina L. Kopobayeva
National Academy of Sciences «Karaganda Medical University»; Karaganda Branch of the KMPA, Karaganda
2 shared publications - Lazzat Begimbekova
Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent
2 shared publications
Latest Publications
- Open Access
Expert Consensus on Optimizing the Strategy for the Prevention of Vitamin D Deficiency in Central Asia: From Scientific Evidence to Real-World Practice
Background/Objectives: Vitamin D deficiency and insufficiency represent a widespread problem in the majority of Central Asian countries, attributable to the geographical location of the region, urbanization, and dietary patterns of the population. Given that vitamin D not only participates in the regulation of calcium and phosphate metabolism but also exerts pleiotropic effects on various organs and systems, its insufficiency and deficiency are associated with a broad spectrum of pathological conditions, ranging from asymptomatic manifestations to severe clinical symptoms, including the development of autoimmune diseases, metabolic disorders, cardiovascular, gynecological and reproductive, and rheumatological conditions. The development of national and interdisciplinary guidelines addressing the diagnosis, prevention of insufficiency, and correction of vitamin D deficiency in the countries of Central Asia represents an important step toward the establishment of effective preventive programs and treatment strategies, which may contribute to a reduction in the prevalence of diseases associated with vitamin D deficiency. The aim of the present work is to formulate a resolution capturing the conclusions and recommendations derived from an interdisciplinary expert discussion. Methods: An Expert Council meeting with the participation of specialists in endocrinology, obstetrics and gynecology, rheumatology, clinical pharmacology, and other medical disciplines from Central Asian and European countries was conducted in Almaty (Kazakhstan) on 18 June 2025. During this meeting, the pleiotropic action of vitamin D was extensively discussed basing on RCTs and observational studies. Results: Following the Expert Council meeting, current international clinical guidelines, scientific research data, and relevant epidemiological evidence were reviewed, leading to the formulation of a resolution that reflects the agreed-upon recommendations for the prevention of vitamin D insufficiency and the correction of vitamin D deficiency across different age groups according to baseline vitamin D metabolite levels. Conclusions: The expert discussion emphasized the need for unified interdisciplinary approaches to the diagnosis, correction, and prevention of vitamin D deficiency in the countries of Central Asia. The proposed recommendations may serve as a foundation for the development of national clinical protocols and the implementation of effective preventive and therapeutic strategies in the countries of Central Asia.
Open AccessExpert Consensus on Optimizing the Strategy for the Prevention of Vitamin D Deficiency in Central Asia: From Scientific Evidence to Real-World Practice
Background/Objectives: Vitamin D deficiency and insufficiency represent a widespread problem in the majority of Central Asian countries, attributable to the geographical location of the region, urbanization, and dietary patterns of the population. Given that vitamin D not only participates in the regulation of calcium and phosphate metabolism but also exerts pleiotropic effects on various organs and systems, its insufficiency and deficiency are associated with a broad spectrum of pathological conditions, ranging from asymptomatic manifestations to severe clinical symptoms, including the development of autoimmune diseases, metabolic disorders, cardiovascular, gynecological and reproductive, and rheumatological conditions. The development of national and interdisciplinary guidelines addressing the diagnosis, prevention of insufficiency, and correction of vitamin D deficiency in the countries of Central Asia represents an important step toward the establishment of effective preventive programs and treatment strategies, which may contribute to a reduction in the prevalence of diseases associated with vitamin D deficiency. The aim of the present work is to formulate a resolution capturing the conclusions and recommendations derived from an interdisciplinary expert discussion. Methods: An Expert Council meeting with the participation of specialists in endocrinology, obstetrics and gynecology, rheumatology, clinical pharmacology, and other medical disciplines from Central Asian and European countries was conducted in Almaty (Kazakhstan) on 18 June 2025. During this meeting, the pleiotropic action of vitamin D was extensively discussed basing on RCTs and observational studies. Results: Following the Expert Council meeting, current international clinical guidelines, scientific research data, and relevant epidemiological evidence were reviewed, leading to the formulation of a resolution that reflects the agreed-upon recommendations for the prevention of vitamin D insufficiency and the correction of vitamin D deficiency across different age groups according to baseline vitamin D metabolite levels. Conclusions: The expert discussion emphasized the need for unified interdisciplinary approaches to the diagnosis, correction, and prevention of vitamin D deficiency in the countries of Central Asia. The proposed recommendations may serve as a foundation for the development of national clinical protocols and the implementation of effective preventive and therapeutic strategies in the countries of Central Asia.
- Open Access
- 17 April 2026
- Published by Publishing Office TRILIST
- No. 82
Resolution of the VII International Forum of Experts on Menopausal Hormone Therapy
The VII International Forum of Experts on Menopausal Hormone Therapy (MHT) was held in Kyiv on November 18, 2025. The modern approach to the MHT prescription is not to resolve the issue of its appropriateness, but to choose the optimal form for a particular woman. Different routes of hormone administration have different pharmacokinetic properties and effects on metabolism, the coagulation system, and women’s somatic health. The recommendations of the European Menopause and Andropause Society emphasize the appropriateness of using combined MHT to improve the glycemic profile and delay the development of diabetes mellitus, with a preference for metabolically neutral progestogens – progesterone and dydrogesterone.Transdermal estrogens enter the systemic circulation directly, minimizing the effect on the liver and coagulation, which makes them the method of choice for women with an increased risk of venous thrombosis, obesity, or hypertriglyceridemia. At the same time, the effectiveness of transdermal MHT is characterized by significant interindividual variability.MHT is an effective antiresorptive method for the prevention of osteoporosis and fractures. Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone. Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases. The individual choice of the form of MHT is a key factor in its safety and clinical efficacy.Particular attention should be paid to oncological safety, particularly the risk of breast cancer, when selecting MHT in patients using a levonorgestrel-releasing intrauterine system. Data from systematic reviews and meta-analyses indicate that the use of estrogens does not increase this risk, while it largely depends on the type of progestogen. Progesterone and dydrogesterone have the most favorable safety profile for the breast compared with synthetic gestagens, which is confirmed by the results of large-scale studies.Psychoemotional and sexual disorders (anxiety, depression, sleep disorders, and decreased libido) are common in perimenopause and are largely due to systemic estrogen deficiency, which affects neurometabolic, vascular, and neuroendocrine homeostasis. The high frequency of these disorders justifies the need for comprehensive diagnostic assessment and individualized MHT in perimenopausal women.
- 17 April 2026
- Published by Publishing Office TRILIST
- No. 82
Open AccessResolution of the VII International Forum of Experts on Menopausal Hormone Therapy
The VII International Forum of Experts on Menopausal Hormone Therapy (MHT) was held in Kyiv on November 18, 2025. The modern approach to the MHT prescription is not to resolve the issue of its appropriateness, but to choose the optimal form for a particular woman. Different routes of hormone administration have different pharmacokinetic properties and effects on metabolism, the coagulation system, and women’s somatic health. The recommendations of the European Menopause and Andropause Society emphasize the appropriateness of using combined MHT to improve the glycemic profile and delay the development of diabetes mellitus, with a preference for metabolically neutral progestogens – progesterone and dydrogesterone.Transdermal estrogens enter the systemic circulation directly, minimizing the effect on the liver and coagulation, which makes them the method of choice for women with an increased risk of venous thrombosis, obesity, or hypertriglyceridemia. At the same time, the effectiveness of transdermal MHT is characterized by significant interindividual variability.MHT is an effective antiresorptive method for the prevention of osteoporosis and fractures. Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone. Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases. The individual choice of the form of MHT is a key factor in its safety and clinical efficacy.Particular attention should be paid to oncological safety, particularly the risk of breast cancer, when selecting MHT in patients using a levonorgestrel-releasing intrauterine system. Data from systematic reviews and meta-analyses indicate that the use of estrogens does not increase this risk, while it largely depends on the type of progestogen. Progesterone and dydrogesterone have the most favorable safety profile for the breast compared with synthetic gestagens, which is confirmed by the results of large-scale studies.Psychoemotional and sexual disorders (anxiety, depression, sleep disorders, and decreased libido) are common in perimenopause and are largely due to systemic estrogen deficiency, which affects neurometabolic, vascular, and neuroendocrine homeostasis. The high frequency of these disorders justifies the need for comprehensive diagnostic assessment and individualized MHT in perimenopausal women.
- Open Access
- 15 March 2024
- Published by Publishing Office TRILIST
- No. 71
V International expert forum on menopausal hormone therapy
On November 23, 2023, the V International Forum of Experts on Menopausal Hormone Therapy (MHT) was held. The Expert Council’s working group included leading experts in the field of endocrine gynaecology and related areas from Azerbaijan, Armenia, Georgia, Kazakhstan, Moldova, Uzbekistan, and Ukraine.The Forum experts noted the importance of dialogue and understanding between doctor and patient, the need for interdisciplinary integration between doctors of those specialties that deal with women’s health issues. Close cooperation with related specialists who provide care to women is necessary, as they are often the ones who encounter the first manifestations of menopause in patients and can therefore refer them to an obstetrician-gynaecologist in a timely manner. The experts reviewed the issue of cardiovascular risk and MHT and determined the following benefit/risk ratio for the cardiovascular effects of MHT:• MHT is not recommended for women at high cardiovascular risk or with previous cardiovascular disease;• MHT may reduce the risk of CVD-related all-cause death in women < 60 years of age and with menopause of up to 10 years;• timely initiation of MHT (in women under 60 years of age or within 10 years of menopause) has the greatest cardiovascular health benefits.The forum updated the Algorithm for prescribing MHT in premature and early menopause and addressed the management of women with polycystic ovary syndrome in menopause. Since the majority of women with this syndrome are overweight and obese, they should use the most metabolically neutral drugs, i.e. those containing didrogesterone or progesterone, for MHT. MHT with didrogesterone has a favourable safety profile in relation to the most common risks of MHT: does not increase the risk of breast cancer and venous thromboembolism, has a favourable safety profile with respect to the endometrium, and does not affect metabolism.
- 15 March 2024
- Published by Publishing Office TRILIST
- No. 71
Open AccessV International expert forum on menopausal hormone therapy
On November 23, 2023, the V International Forum of Experts on Menopausal Hormone Therapy (MHT) was held. The Expert Council’s working group included leading experts in the field of endocrine gynaecology and related areas from Azerbaijan, Armenia, Georgia, Kazakhstan, Moldova, Uzbekistan, and Ukraine.The Forum experts noted the importance of dialogue and understanding between doctor and patient, the need for interdisciplinary integration between doctors of those specialties that deal with women’s health issues. Close cooperation with related specialists who provide care to women is necessary, as they are often the ones who encounter the first manifestations of menopause in patients and can therefore refer them to an obstetrician-gynaecologist in a timely manner. The experts reviewed the issue of cardiovascular risk and MHT and determined the following benefit/risk ratio for the cardiovascular effects of MHT:• MHT is not recommended for women at high cardiovascular risk or with previous cardiovascular disease;• MHT may reduce the risk of CVD-related all-cause death in women < 60 years of age and with menopause of up to 10 years;• timely initiation of MHT (in women under 60 years of age or within 10 years of menopause) has the greatest cardiovascular health benefits.The forum updated the Algorithm for prescribing MHT in premature and early menopause and addressed the management of women with polycystic ovary syndrome in menopause. Since the majority of women with this syndrome are overweight and obese, they should use the most metabolically neutral drugs, i.e. those containing didrogesterone or progesterone, for MHT. MHT with didrogesterone has a favourable safety profile in relation to the most common risks of MHT: does not increase the risk of breast cancer and venous thromboembolism, has a favourable safety profile with respect to the endometrium, and does not affect metabolism.